DistantNews
Support us
SCMeditech Secures Kolon Pharmaceutical as First Client, Kicks Off Human Tissue CDMO Operations
🇰🇷 South Korea /Health & Science

SCMeditech Secures Kolon Pharmaceutical as First Client, Kicks Off Human Tissue CDMO Operations

From Chosun Ilbo · () Korean

Translated from Korean, summarized and contextualized by DistantNews.

At a glance

News Sources not specified New plan
  • SCMeditech has secured Kolon Pharmaceutical as its first client for human tissue-based CDMO services.
  • The companies will collaborate on developing and producing skin boosters using human extracellular matrix (hECM).
  • This partnership marks SCMeditech's official entry into the human tissue CDMO market.

SCMeditech, a company specializing in the research and manufacturing of orthopedic and dental implants, has officially entered the human tissue contract development and manufacturing organization (CDMO) market. The company announced Kolon Pharmaceutical as its inaugural client.

The partnership will focus on the development and production of skin boosters, products designed to improve skin hydration and elasticity through injection. SCMeditech and Kolon Pharmaceutical will leverage human extracellular matrix (hECM) derived from human tissues for these products.

SCMeditech and Kolon Pharmaceutical have signed a CDMO agreement for the development, production, and supply of products utilizing hECM. This collaboration signifies a significant step for SCMeditech as it expands its business scope into the regenerative medicine and aesthetic sectors, building on its existing expertise in biomaterials.

DistantNews Editorial

Originally published by Chosun Ilbo in Korean. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog